# GSK oncology growth and strategic expansion

> Live situation record from CLSTR: https://clstr.news/situations/gsk-oncology-growth-and-strategic-expansion
> Updated: 2026-10-19T03:25:15.000Z. Sources: 4. Developments: 2.

GSK has outlined a long-term growth strategy aiming for sales exceeding £40 billion, driven largely by its oncology portfolio. To support this target and offset upcoming patent expirations for HIV medicines, the company is implementing a simplification program intended to generate £1.9 billion in savings.

As part of its expansion in cancer therapies, GSK finalized an exclusive licensing agreement with a subsidiary of HUTCHMED for the experimental therapy HMPL-A830. This antibody-drug conjugate targets KRAS and EGFR to treat colorectal, pancreatic, and lung cancers. The deal includes a $110 million upfront payment to HUTCHMED, with potential milestone payments totaling up to $1.295 billion.

## Timeline

### 2026-10-19: GSK and HUTCHMED sign cancer therapy licensing deal

GSK has secured global rights, excluding Greater China, for HUTCHMED’s experimental KRAS/EGFR-targeting cancer therapy HMPL-A830 in a deal worth up to $1.295 billion.

2 sources. https://clstr.news/cluster/gsk-and-hutchmed-sign-cancer-therapy-licensing-deal

### 2026-09-22: GSK targets £40B in sales through oncology growth and cost-savings

GSK aims for over £40 billion in sales, driven by an oncology push and a £1.9 billion cost-savings plan to fund pipeline development.

2 sources. https://clstr.news/cluster/gerdau-evp-sells-51800-shares-amid-strong-quarterly-revenue

---
Cite as: GSK oncology growth and strategic expansion. CLSTR, https://clstr.news/situations/gsk-oncology-growth-and-strategic-expansion